Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?
absolute risk
misclassification
remaining lifetime risk
risk threshold
risk-stratified screening
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
15 Sep 2021
15 Sep 2021
Historique:
received:
05
08
2021
revised:
03
09
2021
accepted:
13
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
In risk-stratified cancer screening, multiple risk factors are incorporated into the risk assessment. An individual's estimated absolute cancer risk is linked to risk categories with tailored screening recommendations for each risk category. Absolute risk, expressed as either remaining lifetime risk or shorter-term (five- or ten-year) risk, is estimated from the age at assessment. These risk estimates vary by age; however, some clinical guidelines (e.g., enhanced breast cancer surveillance guidelines) and ongoing personalised breast screening trials, stratify women based on absolute risk thresholds that do not vary by age. We examine an alternative approach in which the risk thresholds used for risk stratification vary by age and consider the implications of using age-independent risk thresholds on risk stratification. We demonstrate that using an age-independent remaining lifetime risk threshold approach could identify high-risk younger women but would miss high-risk older women, whereas an age-independent 5-year or 10-year absolute risk threshold could miss high-risk younger women and classify lower-risk older women as high risk. With risk misclassification, women with an equivalent risk level would be offered a different screening plan. To mitigate these problems, age-dependent absolute risk thresholds should be used to inform risk stratification.
Identifiants
pubmed: 34575693
pii: jpm11090916
doi: 10.3390/jpm11090916
pmc: PMC8469877
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Genome Canada
ID : 13529
Organisme : CIHR
ID : 155865
Pays : Canada
Références
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
J Natl Cancer Inst. 2015 May 08;107(7):
pubmed: 25956172
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Ann Intern Med. 2008 Mar 4;148(5):337-47
pubmed: 18316752
PLoS Med. 2019 Dec 20;16(12):e1002998
pubmed: 31860675
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
J Pers Med. 2021 Jun 04;11(6):
pubmed: 34199804
J Natl Cancer Inst. 1993 Jun 2;85(11):892-7
pubmed: 8492317
Int J Epidemiol. 2018 Apr 1;47(2):526-536
pubmed: 29315403
Breast Cancer Res. 2021 Feb 15;23(1):22
pubmed: 33588869
J Natl Cancer Inst. 2021 Apr 6;113(4):434-442
pubmed: 32853342
Curr Oncol. 2016 Dec;23(6):e615-e625
pubmed: 28050152
Nat Genet. 2002 May;31(1):33-6
pubmed: 11984562
JAMA Oncol. 2018 Nov 1;4(11):1504-1510
pubmed: 29978189
Nat Genet. 2013 Apr;45(4):400-5, 405e1-3
pubmed: 23455638
NPJ Breast Cancer. 2017 Sep 13;3:34
pubmed: 28944288